The EAU updated their guidelines to include annual PSA screening in men with BRCA2 pathogenic variants from age 40 years, based on the results of the BRCA1 and BRCA2 cohorts of the IMPACT study (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in men at higher genetic risk and controls).24, 25, 26. The gene discussed is BRCA2; the disease is prostate carcinoma.